Monoclonal antibody against NRP-1 b1b2

Hybridoma

Volumn 30, Issue 4, 2011, Pages 369-373

  Li, Xiang ^a   Luo, Fanghong ^a   Wang, Shengyu ^a   Ni, Erru ^a   Tang, Xiaoyong ^a   Lv, Haiyan ^a   Chen, Xiaoli ^a   Chen, Lukui ^a   Yan, Jianghua ^a  

^a XIAMEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; IMMUNOGLOBULIN G1 ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY NRP 1 B1B2; NEUROPILIN; NEUROPILIN 1 B1B2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY SPECIFICITY; ARTICLE; CANCER CELL CULTURE; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; HYBRIDOMA CELL CULTURE; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY SPECIFICITY; BLOTTING, WESTERN; CELLS, CULTURED; CLONING, MOLECULAR; ESCHERICHIA COLI; FEMALE; GENETIC VECTORS; HUMANS; HYBRIDOMAS; MICE; MICE, INBRED BALB C; NEUROPILIN-1; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS;

EID: 80052011661     PISSN: 15540014     EISSN: 15578348     Source Type: Journal    
DOI: 10.1089/hyb.2011.0012     Document Type: Article

References (15)

1. He Z, and Tessier-Lavigne M: Neuropilin is a receptor for the axonal chemorepellent Semaphorin III. Cell 1997;90:739-751. (Pubitemid 27357965)
2. Soker S, Takashima S, Miao HQ, Neufeld G, and Klagsbrun M: Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998;92:735-745. (Pubitemid 28155313)
3. Klagsbrun M, Takashima S, and Mamluk R: The role of neuropilin in vascular and tumor biology. Adv Exp Med Biol 2002;515:33-48. (Pubitemid 36324180)
4. Beckmann G, and Bork P: An adhesive domain detected in functionally diverse receptors. Trends Biochem Sci 1993; 18:40-41. (Pubitemid 23145108)
5. Vander Kooi CW, Jusino MA, Perman B, Neau DB, Bellamy HD, and Leahy DJ: Structural basis for ligand and heparin binding to neuropilin B domains. Proc Natl Acad Sci USA 2007;104:6152-6157. (Pubitemid 47186064)
6. Whitaker GB, Limberg BJ, and Rosenbaum JS: Vascular en-dothelial growth receptor-2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF165 and VEGF121. J Biol Chem 2001; 276:25520-25531.
7. Kohler G, and Milstein C: Derivation of specific antibody producing tissue culture and tumor lines by cell fusion. Eur J Immunol 1976;6:511-519.
8. Kim KJ, Alphonso M, Schmelzer CH, and Lowe D: Detection of human leukemia inhibitory factor by monoclonal antibody based ELISA. J Immunol Method 1992;156(1):9-17.
9. Ey PL, Prowse SJ, and Jenkin CR: Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose. Immunochemistry 1978;15:429-436. (Pubitemid 9015373)
10. Herzog Y, Kalcheim C, Kahane N, Reshef R, and Neufeld G: Differential expression of neuropilin-1 and neuropilin-2 in arteries and veins. Mech Dev 2001;109:115-119. (Pubitemid 33035924)
11. Yuan L, Moyon D, Pardanaud L, Breant C, Karkkainen MJ, Alitalo K, and Eichmann A: Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development 2002;129:4797-4806. (Pubitemid 35282411)
12. Soker S, Takashima S, Miao HQ, Neufeld G, and Klagsbrun M: Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998;92:735-745. (Pubitemid 28155313)
13. Gu C, Rodriguez ER, Reimert DV, Shu T, Fritzsch B, Richards LJ, Kolodkin AL, and Ginty DD: Neuropilin-1 conveys semaphoring and VEGF signaling during neural and cardiovascular development. Dev Cell 2003;5:45-57. (Pubitemid 36827341)
14. Kerbel RS, Yu J, Tran J, Man S, Viloria-Petit A, Klement G, Coomber BL, and Rak J: Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev 2001;20:79-86. (Pubitemid 34074682)
15. Jain RK, Duda DG, Clark JW, and Loeffler JS: Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3:24-40. (Pubitemid 43108832)